InNexus Biotechnology Inc. (TSX:IXS.V), a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announces that it has, effective August 26, 2011, granted incentive stock options to purchase an aggregate of 1,068,683 common shares without par value in the capital of the Company to certain persons who are either a director, officer, employee or consultant of the Company. The stock options will be exercisable for a period 5 years expiring on August 27, 2016 at a price of $0.05 per common share.
The Options will vest equally on a quarterly basis, over a period of 18 months, or will vest immediately in the event of a change of control of the Company or (at the discretion of the Board of Directors) takeover bid, subject to the approval of the TSX Venture Exchange.
The granting of the foregoing incentive stock options is subject to acceptance by the TSX Venture Exchange.
Neurolentech signs technology access partnership with Kaerus Bioscience to advance neurodevelopmental disorder research